Cadila Healthcare is on radar
DSIJ Intelligence / 21 Nov 2016
Cadila Healthcare has received the final approval from the USFDA to market Metronidazole Tablets USP in strengths of 250 mg and 500 mg.
Cadila Healthcare has received the final approval from the USFDA to market Metronidazole Tablets USP in strengths of 250 mg and 500 mg. The drug which is used to treat infections caused by bacteria or parasites will be produced at the group’s formulations manufacturing facility at Baddi.
Zydus Group has more than 105 approvals and has so far filed nearly 275 ANDAs since the commencement of the filing process.
Cadila Healthcare will transfer its India human formulations business to its wholly-owned subsidiary Zydus Healthcare on a slump sale basis for Rs 69.3 crore. The company’s Indian human formulations business had turnover of Rs 1371 crore in FY16, contributing about 21 per cent of its total turnover.
The share price of Cadila Healthcare had declined by 1.25 per cent on bourses in early trades; and is trading at Rs 371.5 on intraday basis.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.